NCT07022678 Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Status NOT_YET_RECRUITING Phase PHASE3
NCT07012447 Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations Status RECRUITING Phase PHASE2
NCT06930352 Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Status NOT_YET_RECRUITING Phase PHASE2
NCT06928662 Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Status RECRUITING Phase PHASE1/PHASE2
NCT06918431 Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Status RECRUITING Phase PHASE2
NCT06917911 Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) Status RECRUITING Phase PHASE2
NCT06905509 Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Status RECRUITING Phase PHASE2
NCT06895473 Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome Status RECRUITING Phase PHASE2
NCT06854003 BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Status RECRUITING Phase PHASE2
NCT06763666 CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML Status NOT_YET_RECRUITING Phase PHASE4
NCT06744556 HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06744504 Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 Status RECRUITING Phase PHASE3
NCT06643962 Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy Status RECRUITING Phase NA
NCT06635681 Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML Status RECRUITING Phase PHASE2
NCT06621212 Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML Status RECRUITING Phase PHASE2
NCT06621199 Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML Status RECRUITING Phase PHASE2
NCT06561880 The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation Status RECRUITING Phase PHASE1/PHASE2
NCT06561152 Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML Status RECRUITING Phase PHASE1/PHASE2
NCT06554626 Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL Status RECRUITING Phase PHASE2